It looks like the days of financial ledgerdemain are coming to a close. As a humble suggestion, maybe drug companies should be run by people who know about patients and medicine, not financial pukes and consulting clones.
perhaps you should stop laughing clown and do a little research.
We lower our 12-month target $28 to $60 on below peers 12.9x our 2016 EPS estimate of $4.65,
down from $5.97. We lower '17's to $5.80 from $7.02. Sales,including Auxilium and Par
Pharmaceuticals, rose 35% but Voltaren sales fell 21% and we now see 2016 sales of $3.9B, down
from $4.4B as ENDP faces generic challenges to Voltaren and we see delays on regulatory
actions on some ENDP products. Q1 EPS of $1.08 vs. $1.17 is $0.23 below our estimate. We expect
the shares to remain volatile in 2016 but believe the shares now trading at 5.7x our lowered 2016
EPS are attractively valued.
Jeffrey Loo, CFA
The reality is somewhere in between S&P's upper limit and Mizuho's lower limit. The average of the two is $36.50. If they beat estimates and raise guidance in 2H16 (inflection points of BALBUCA and Xiaflex), I see that number printing around Christmas...
Are you suddenly going to believe Mizuho now? If so, you would have been buying for the past month with his $42 target. BTW, it was $83 late last year! The ANALyst cannot come up with a reasonable estimate even if his life depended on it. Do your own analysis and decide accordingly. A PE of 5 and 10% discount to book sounds reasonable to me or about $22-23/share. And we go from there according to changes in fundamentals. I see my target reached in the next month or two. Looking to accumulate more below 10 year lows...
you seem to struggle with facts:
Endo earned $4.87/ share in 2015.
cash flow per share was $7.05.
$7.05 x 222 mil shares = $1.56 billion in cash flow.
now sheep----don't you feel a little embarrassed?
Roger H Kimmel , director of Endo International Plc purchased 7,000 shares on May 10, 2016. The Insider buying transaction was reported by the company on May 11, 2016 to the Securities and Exchange Commission. The shares were purchased at $15.57 per share for a total value of $108,720.00 , the company said in a SEC Form 4 Filing.
I laughed when I read Chiradeep's article. Rarely do you see a story as 1 sided as his without offering any new information. Guess the noob doesn't worry about valuation. Hope the few rupees he got he puts to good use. Maybe his followup article will be best suited for the Motley Fool.
is undervaluaed unless the is something really big and bad coming. Analyst know nothing get paid for hot air. When there is blood on the street BUY good luck IMHO
For 2016 , we project:
• Adjusted EBITDA of ~$2 billion
• Underlying cash from operations* of greater than $800 million
So you have a company that is trading for $26 going to make 2 billion in 2016. On top of that, we have institutional investors combined with shorts owning more then 100% outstanding shares.
Pop Pop Pop
More to come. This is the best that can happen to anyone that likes money. Buying a $40 stock for $13
Endo International is Now Oversold (ENDP)
By BNK Invest, May 06, 2016, 12:11:27 PM EDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Friday, shares of Endo International plc (Symbol: ENDP) entered into oversold territory, hitting an RSI reading of 23.3, after changing hands as low as $15.85 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 41.4. A bullish investor could look at ENDP's 23.3 RSI reading today as sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side.
I rode through a similar circumstance with Tyco a number of years ago... This is not risk free endeaver but I made a boat load of money after riding a good deal of turbulence for a year or so with Tyco...
The bad news will continue with ENDO for awhile - expect unfounded rumors about bankruptcy to surface along with the inevitable lawsuits. Sometimes it takes more stomach than brains to ride these things out and profit...
May 11, 2016 Mark Robinson
Director Arthur J. Higgins purchased 11,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 10th. The stock was acquired at an average cost of $15.42 per share, with a total value of $169,620.00. Following the transaction, the director now directly owns 45,623 shares of the company’s stock, valued at $703,506.66. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
it is very clear that ENDP is not INSY and yet is getting crushed as a results of INSY results. For God Sake, INSY is a (1) drug company who has an annual net sales of approx. $340 millions. On the other hand, ENDP has numerous products on the market that are generating close to 5 billions in sales. If u check ENDP 2015
annual earning release results u will come to realize that their earnings is actually almost equal their current market cap. Time will tell but I really thing at this current level, ENDP offers an extremely excellent long term play and a very low risk/reward at this levels......
Sentiment: Strong Buy
Company's additional accrual of $843 million for the mesh litigation amounts to an impact of $433 million after-tax. On an after-tax basis, litigation will cause a cash flow hit of $150-$250 million in 2016 and $325-$425 million in 2017. Seems like an awful lot, no? But compare it to the $2 billion in EBITDA Company will generate in 2016 and more in 2017. The rate of new case filings has decreased "substantially" so far in 2016, and the Company is hopeful the litigation will be wrapped up by 2017. This company is a cash cow, and these litigation costs, while substantial, are easily managed.
Once Mr. Market crunches the numbers, I suspect he will conclude the spike down was overdone and will rally the stock back to the low 50 area soon. ENDP is a growth company now selling for a ridiculously low PE that is undeserved. I picked up 2000 shares in my trading account today at $42.25 and another 5000 in my IRA at an average cost of $40.50.